biostudies-literatureTorres VENCATS NIH HHSNIDDK NIH HHSNCRR NIH HHS577-85https://www.ebi.ac.uk/biostudies/studies/S-EPMC3580956biostudies-literatureUnknown81(6)HALT PKD consists of two ongoing randomized trials with the largest cohort of systematically studied patients with autosomal dominant polycystic kidney disease to date. Study A will compare combined treatment with an angiotensin-converting inhibitor and receptor blocker to inhibitor alone and standard compared with low blood pressure targets in 558 early-stage disease patients with an eGFR over 60 ml/min per 1.73 m(2). Study B will compare inhibitor-blocker treatment to the inhibitor alone in 486 late-stage patients with eGFR 25-60 ml/min per 1.73 m(2). We used correlation and multiple regression cross-sectional analyses to determine associations of baseline parameters with total kidney, liver, or liver cyst volumes measured by MRI in Study A and eGFR in both studies. Lower eGFR and higherKidney internationalAnalysis of baseline parameters in the HALT polycystic kidney disease trials.PMC3580956M01 RR000051DK62411DK62410RR025008UL1 TR000454U01 DK062410U01 DK062411RR23940RR00585UL1 RR025008M01 RR000039U01 DK062408UL1 RR025780RR000054UL1 RR024150M01 RR000054RR000051RR025752DK62402DK62401U01 DK082230RR000039RR024989DK62408U01 DK062401U01 DK062402UL1 RR024989UL1 RR025752RR024150M01 RR000585M01 RR023940RR025780Chapman ABBost JEMasoumi AHALT PKD Study GroupRemer EBae KTWinklhofer FTBaker DKelleher CMiskulin DCOtto KTorres VEThompson PAMaxwell BHalin NJPatel NAbebe KZHitchcock SBraun WESteinman TIPerkins LSpirko RPedrosa IPerrone RDFlynn GMartin DRWoltman RWatkins DFishman MOndler HJolley AErfort AGlockner JSmith PLanza PMeyers CMWetzel LHOskoui FRMorgan PSimon GHogan MCMiller JPDriggs JSchrier RWfalseAnalysis of baseline parameters in the HALT polycystic kidney disease trials.HALT PKD consists of two ongoing randomized trials with the largest cohort of systematically studied patients with autosomal dominant polycystic kidney disease to date. Study A will compare combined treatment with an angiotensin-converting inhibitor and receptor blocker to inhibitor alone and standard compared with low blood pressure targets in 558 early-stage disease patients with an eGFR over 60 ml/min per 1.73 m(2). Study B will compare inhibitor-blocker treatment to the inhibitor alone in 486 late-stage patients with eGFR 25-60 ml/min per 1.73 m(2). We used correlation and multiple regression cross-sectional analyses to determine associations of baseline parameters with total kidney, liver, or liver cyst volumes measured by MRI in Study A and eGFR in both studies. Lower eGFR and higher2012-01-01T00:00:00Z2012 Mar2025-04-18T17:02:55.533Z2019-03-26T23:05:23ZS-EPMC35809562220535510.1038/ki.2011.411